---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-075777"
form_type: "8-K"
ticker: "PTGX"
cik: "0001377121"
company_name: "Protagonist Therapeutics, Inc"
filed_at: "2026-06-18T20:30:53+00:00"
generated_at: "2026-06-18T20:39:33.581360+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Protagonist Therapeutics stockholders approve 2026 equity plan, adding 650K new shares

## Summary
- Stockholders approved adoption of 2026 Equity Incentive Plan, replacing 2016 plan; adds 650,000 new shares plus carryover from prior plan and returning shares.
- Dinesh Patel and Lewis Williams re-elected as Class I directors with 48.7M and 45.4M votes for, respectively.
- Say-on-pay passed: 53.4M for, 3.2M against; Ernst & Young ratified as independent auditor (59.4M for, 28K against).
- Plan approval received 47.7M for, 8.8M against; broker non-votes of 2.8M on all proposals except auditor ratification.

## SEC filing metadata
- accession: 0001104659-26-075777
- form_type: 8-K
- ticker: PTGX
- cik: 0001377121
- company_name: Protagonist Therapeutics, Inc
- filed_at: 2026-06-18T20:30:53+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1377121/000110465926075777/0001104659-26-075777-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1377121/000110465926075777/tm2618251d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-075777
- JSON: https://secwatch.observer/filing/0001104659-26-075777.json
- Plain text: https://secwatch.observer/filing/0001104659-26-075777.txt

## Key facts
- Shareholder Votes
  Protagonist Therapeutics, Inc shareholders approved Approval, on a non-binding advisory basis, of the compensation of the named executive officers.
  - Proposal: say on pay
  - Outcome: passed
  source text: Proposal 2 — To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers. This proposal was approved by the requisite vote, with the votes thereon as follows: Final Voting Results For Against Abstentions Broker Non-Votes 53,412,559 3,164,702 12,752 2,819,234
  evidence_url: https://www.sec.gov/Archives/edgar/data/1377121/000110465926075777/0001104659-26-075777-index.htm
- Shareholder Votes
  Protagonist Therapeutics, Inc shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-12-31 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-12-31
  source text: Proposal 3 — To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2026. This proposal was approved by the requisite vote, with the votes thereon as follows: Final Voting Results For Against Abstentions Broker Non-Votes 59,371,487 28,221 9,539 —
  evidence_url: https://www.sec.gov/Archives/edgar/data/1377121/000110465926075777/0001104659-26-075777-index.htm
- Shareholder Votes
  Protagonist Therapeutics, Inc shareholders approved Election of two Class I director nominees.
  - Proposal: director election
  - Outcome: passed
  source text: Proposal 1 — To elect the two Class I director nominees to hold office until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified. Each of the two nominees was so elected, with the votes thereon as follows: Final Voting Results Nominee For Withheld Broker Non-Votes Dinesh V. Patel, Ph.D. 48,714,702 7,875,311 2,819,234 Lewis T. “Rusty” Williams, M.D., Ph.D. 45,371,193 11,218,820 2,819,234
  evidence_url: https://www.sec.gov/Archives/edgar/data/1377121/000110465926075777/0001104659-26-075777-index.htm
- Shareholder Votes
  Protagonist Therapeutics, Inc shareholders approved Approval of the adoption of the Company’s 2026 Equity Incentive Plan.
  - Proposal: equity plan
  - Outcome: passed
  source text: Proposal 4 — To approve the adoption of the Company’s 2026 Equity Incentive Plan. This proposal was approved by the requisite vote, with the votes thereon as follows: Final Voting Results For Against Abstentions Broker Non-Votes 47,745,562 8,826,703 17,748 2,819,234
  evidence_url: https://www.sec.gov/Archives/edgar/data/1377121/000110465926075777/0001104659-26-075777-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.